Use of subatmospheric (VAC) therapy to improve bioengineered tissue grafting in diabetic foot wounds

Eric H. Espensen, Brent P. Nixon, Lawrence A. Lavery, David G. Armstrong

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The use of bioengineered tissue and topical subatmospheric pressure therapy have both been widely accepted as adjunctive therapies for the treatment of noninfected, nonischemic diabetic foot wounds. This article describes a temporally overlapping method of care that includes a period of simultaneous application of bioengineered tissue (Apligraf, Novartis Pharmaceuticals Corp, East Hanover, New Jersey) and subatmospheric pressure therapy delivered through the VAC (Vacuum Assisted Closure) system (KCI, Inc, San Antonio, Texas). Future descriptive and analytic works may test the hypothesis that combined therapies used at different and often overlapping periods during the wound-healing cycle may be more effective than a single modality.

Original languageEnglish (US)
Pages (from-to)395-397
Number of pages3
JournalJournal of the American Podiatric Medical Association
Volume92
Issue number7
StatePublished - Jul 2002

Fingerprint

Negative-Pressure Wound Therapy
Tissue Transplantation
Diabetic Foot
Wounds and Injuries
Therapeutics
Pressure
Wound Healing
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Use of subatmospheric (VAC) therapy to improve bioengineered tissue grafting in diabetic foot wounds. / Espensen, Eric H.; Nixon, Brent P.; Lavery, Lawrence A.; Armstrong, David G.

In: Journal of the American Podiatric Medical Association, Vol. 92, No. 7, 07.2002, p. 395-397.

Research output: Contribution to journalArticle

@article{91aa60a3fa7f4740b38f1348932c96a0,
title = "Use of subatmospheric (VAC) therapy to improve bioengineered tissue grafting in diabetic foot wounds",
abstract = "The use of bioengineered tissue and topical subatmospheric pressure therapy have both been widely accepted as adjunctive therapies for the treatment of noninfected, nonischemic diabetic foot wounds. This article describes a temporally overlapping method of care that includes a period of simultaneous application of bioengineered tissue (Apligraf, Novartis Pharmaceuticals Corp, East Hanover, New Jersey) and subatmospheric pressure therapy delivered through the VAC (Vacuum Assisted Closure) system (KCI, Inc, San Antonio, Texas). Future descriptive and analytic works may test the hypothesis that combined therapies used at different and often overlapping periods during the wound-healing cycle may be more effective than a single modality.",
author = "Espensen, {Eric H.} and Nixon, {Brent P.} and Lavery, {Lawrence A.} and Armstrong, {David G.}",
year = "2002",
month = "7",
language = "English (US)",
volume = "92",
pages = "395--397",
journal = "Journal of the American Podiatric Medical Association",
issn = "8750-7315",
publisher = "American Podiatric Medical Association",
number = "7",

}

TY - JOUR

T1 - Use of subatmospheric (VAC) therapy to improve bioengineered tissue grafting in diabetic foot wounds

AU - Espensen, Eric H.

AU - Nixon, Brent P.

AU - Lavery, Lawrence A.

AU - Armstrong, David G.

PY - 2002/7

Y1 - 2002/7

N2 - The use of bioengineered tissue and topical subatmospheric pressure therapy have both been widely accepted as adjunctive therapies for the treatment of noninfected, nonischemic diabetic foot wounds. This article describes a temporally overlapping method of care that includes a period of simultaneous application of bioengineered tissue (Apligraf, Novartis Pharmaceuticals Corp, East Hanover, New Jersey) and subatmospheric pressure therapy delivered through the VAC (Vacuum Assisted Closure) system (KCI, Inc, San Antonio, Texas). Future descriptive and analytic works may test the hypothesis that combined therapies used at different and often overlapping periods during the wound-healing cycle may be more effective than a single modality.

AB - The use of bioengineered tissue and topical subatmospheric pressure therapy have both been widely accepted as adjunctive therapies for the treatment of noninfected, nonischemic diabetic foot wounds. This article describes a temporally overlapping method of care that includes a period of simultaneous application of bioengineered tissue (Apligraf, Novartis Pharmaceuticals Corp, East Hanover, New Jersey) and subatmospheric pressure therapy delivered through the VAC (Vacuum Assisted Closure) system (KCI, Inc, San Antonio, Texas). Future descriptive and analytic works may test the hypothesis that combined therapies used at different and often overlapping periods during the wound-healing cycle may be more effective than a single modality.

UR - http://www.scopus.com/inward/record.url?scp=0036636699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036636699&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 395

EP - 397

JO - Journal of the American Podiatric Medical Association

JF - Journal of the American Podiatric Medical Association

SN - 8750-7315

IS - 7

ER -